Immunotherapy for Cancer

JP2023553352A5Active Publication Date: 2024-12-03THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532220
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-26
Filing Date
2021-11-26
Publication Date
2024-12-03
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

Current cancer vaccines lack effective adjuvants that can activate the cGAS-STING pathway to induce potent anti-tumor immune responses, and existing STING agonists are less effective in humans due to their inability to enter cells and activate different forms of the STING protein.

Method used

The use of polyglucosamine and acetylated polyglucosamine adjuvants, which are highly deacetylated forms of chitosan, to activate the cGAS-STING pathway by efficiently entering cells and inducing mitochondrial reactive oxygen species (mtROS), leading to robust anti-tumor immune responses.

Benefits of technology

Polyglucosamine and acetylated polyglucosamine adjuvants demonstrate significant antitumor activity by enhancing immune responses in both prophylactic and therapeutic settings, including synergistic effects with checkpoint inhibitor therapy and direct tumoricidal activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to a method of immunotherapy for the prevention or treatment of cancer in a subject, the method comprising administering to the subject an adjuvant or administering an adjuvant in combination with a tumor antigen, the adjuvant comprising polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, the N-acetyl-D-glucosamine groups being distributed in two or more blocks in the acetylated polyglucosamine.The present invention relates to a method of immunotherapy for solid cancer in a subject, the method comprising administering to the subject polyglucosamine or chitosan, the administration being intratumoral and / or peritumoral.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to immunotherapy for cancer, particularly the use of adjuvants for antitumor vaccines, and related methods and compositions. The present invention further relates to anticancer therapeutic agents, and related methods and compositions. [Background technology]

[0002] Cancer immunotherapy has emerged as a new pillar of cancer treatment, and research in this field has exploded over the past decade, leading to the development of several blockbuster drugs. Cancer vaccines are poised to become the next frontier in this new era of cancer treatment. However, their development has been hampered by the lack of suitable vaccine adjuvants (components of vaccines that help initiate and propagate protective immune responses). Vaccines can be applied to prevent cancer (prophylactic) or to treat existing tumors (therapeutic). A vaccine adjuvant that could be used in both situations would have significant benefits and broader application.

[0003] Cancer therapy utilizing innate immunity is at the forefront of targeted and personalized cancer treatment. Recent studies have revealed that cGAS-STING-dependent innate immune signaling plays a critical role in innate antitumor immunity, spurring considerable interest in developing activators of this pathway as cancer therapeutics. To date, research has focused on cyclic dinucleotide (CDN) analogs. These molecules are synthesized by the enzyme cGAS after detecting DNA in cells. CDNs activate STING, leading to the expression of potent antiviral and anticancer cytokines that trigger adaptive immunity. In fact, intratumoral injection of CDNs has led to the regression of multiple tumor types in mice, leading to their evaluation in phase 1 clinical trials. Unfortunately, these CDN STING agonists have been limited in efficacy in humans, stalling at the phase 1 stage. This failure is thought to be due to their inability to enter cells and activate distinct forms of the STING protein in human populations. Thus, research into translational STING agonists continues. Summary of the Invention

[0004] It is therefore an object of the present invention to provide improved vaccine adjuvants for activation of the cGAS-STING pathway and / or alternative cancer therapies.

[0005] According to a first aspect of the present invention, there is provided a method of immunotherapy for the prevention or treatment of cancer in a subject, the method comprising administering to the subject an adjuvant or administering an adjuvant in combination with a tumor antigen, wherein the adjuvant comprises polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, and the N-acetyl-D-glucosamine groups are distributed in two or more blocks in the acetylated polyglucosamine.

[0006] The present invention advantageously provides an adjuvant with unique potential to promote antitumor immune responses. The carbohydrate polyglucosamine (a 100% deacetylated form of chitin) readily enters cells, efficiently activates cGAS-STING, and has been found to have impressive antitumor function in multiple mouse preclinical models in both preventive and therapeutic settings. The present invention advantageously demonstrates antitumor and STING activity in a human monocytic leukemia cell line (THP1). Vaccination approaches aimed at targeting intracellular pathogens and cancer require components that activate cellular immunity. Currently, there is a lack of suitable adjuvants to elicit such responses. While commercially available chitosan salts have been shown to promote cellular immune responses in vivo after vaccination via intraperitoneal and intranasal routes, they are more limited in their ability to promote such responses via clinically relevant routes (e.g., intramuscular or subcutaneous). In particular, Carroll et al. (2016, Immunity 44, 597-608) previously used Protasan™, a commercially available chitosan with a degree of deacetylation (DD) of 86%. Chitosan was understood to critically rely on the induction of mitochondrial reactive oxygen species (mtROS) to drive mtDNA release, cGAS activation, cGAMP production, and STING activation. Deacetylating chitin to 90–100% significantly increased mtROS levels, and polyglucosamine (a 100% deacetylated form of chitin) significantly elevated these levels. Polyglucosamine-induced dendritic cell activation appears to occur via a distinct mechanism, where the polymer appears to damage the nuclear compartment, allowing nuclear DNA to be released into the cytoplasm, activating the cGAS-STING pathway. Polyglucosamine and chitosan with a degree of deacetylation of at least 90% demonstrated potent antitumor activity in preventative preclinical animal tumor models, significantly outperforming Protasan™ (Figure 5). The antitumor activity of the induced response was demonstrated in a preventative setting using robust preclinical animal tumor models.The elucidation of the mechanism of action of polyglucosamine provides a clear rationale for the use of polyglucosamine and acetylated polyglucosamine (e.g., chitosan that is at least 90% deacetylated) as vaccine adjuvants, as a clear understanding of the mechanism of action of a compound is important for translation into the clinical setting. The adjuvants of the present invention also differ from those discussed in the art (e.g., WO 2020 / 045679) in that they are advantageously free-chain and non-blocking, since, unlike the molecules in WO 2020 / 045679, the free amino groups do not have to be conjugated to, for example, surfactants or TLR agonists.

[0007] According to a second aspect of the present invention, there is provided a method of immunotherapy for solid cancer in a subject, said method comprising administering polyglucosamine or chitosan to said subject, said administration being intratumoral and / or peritumoral.

[0008] Advantageously, the present invention further identifies polyglucosamine (and chitosan) as an effective stand-alone cancer immunotherapy. It is demonstrated herein that intratumoral injection of polyglucosamine (or chitosan) results in significant inhibition of tumor growth in preclinical animal tumor models. Intratumoral injection of polyglucosamine (or chitosan) has a remarkable potential for synergistic effects with checkpoint inhibitors and costimulatory agonist therapy and can be used alone or in combination approaches. The presence of intratumoral immune cells is a prerequisite for successful checkpoint (co-inhibitory receptor) blockade therapy. Intratumoral administration of polyglucosamine (or chitosan) likely results in the influx of immune cells, shifting the tumor from an immunologically "cold" to a "hot" state, and STING agonists such as polyglucosamine have been shown to increase checkpoint expression on immune cells. It is also demonstrated herein that polyglucosamine (or chitosan) can increase the expression of costimulatory molecules in tumor cells themselves (Figure 7). Furthermore, it has been demonstrated that polyglucosamine (or chitosan) can have direct tumoricidal activity, thus demonstrating its remarkable ability to enhance response rates to checkpoint inhibitor therapy, which remain clinically low. [Brief explanation of the drawings]

[0009] [Figure 1] BMDCs phagocytose C100 and Protasan. [Figure 2A] Highly deacetylated chitosan polymers enhance the production of mitochondrial reactive oxygen species. [Figure 2B] Highly deacetylated chitosan polymers enhance the production of mitochondrial reactive oxygen species. [Figure 3A] Highly deacetylated chitosan polymers drive mitochondrial stress in BMDCs. [Figure 3B] Highly deacetylated chitosan polymers drive mitochondrial stress in BMDCs. [Figure 4]Highly deacetylated chitosan polymers are toxic to BMDCs. [Figure 5A] The degree of deacetylation of the polymer determines the extent of type I IFN production and IFNAR-dependent DC maturation. [Figure 5B] The degree of deacetylation of the polymer determines the extent of type I IFN production and IFNAR-dependent DC maturation. [Figure 6A] Chitin-derived polymer-induced inflammasome activation by BMDCs depends on the degree and distribution of deacetylation. [Figure 6B] Chitin-derived polymer-induced inflammasome activation by BMDCs depends on the degree and distribution of deacetylation. [Figure 7A] C100 induces mitochondrial ROS, DC maturation, and inflammasome activation across a broad molecular weight range. [Figure 7B] C100 induces mitochondrial ROS, DC maturation, and inflammasome activation across a broad molecular weight range. [Figure 7C] C100 induces mitochondrial ROS, DC maturation, and inflammasome activation across a broad molecular weight range. [Figure 8] C100 of various molecular weights is a more potent inducer of mtROS and cell death than chitosan polymers with a lower degree of deacylation. [Figure 9] Highly deactylated chitosan polymers are STING agonists. [Figure 10] Low-dose ethidium bromide treatment depletes mtDNA in BMDCs. [Figure 11] C100-induced transcription of ifna and ifnb mRNA does not require mtDNA. [Figure 12] C100 drives robust nuclear DNA fragmentation. [Figure 13] Protosan and C90 do not cause DNA damage in BMDCs. [Figure 14A]Ethidium bromide and C100 treatment drive synergistic DNA damage. [Figure 14B] Ethidium bromide and C100 treatment drive synergistic DNA damage. [Figure 15] Intratumoral delivery of C100 significantly suppresses tumor growth and promotes survival. [Figure 16] C100 and C90 drive potent antigen-specific antitumor immunity in a prophylactic setting. [Figure 17] Intratumoral delivery of C100, C90, and Protasan inhibits tumor growth and promotes prolonged survival. [Figure 18] Enhancement of Th1 immune responses to the TB antigen H56 by subcutaneous administration requires complete deacetylation of chitin. [Figure 19] Prophylactic immunization with 86% deacetylated chitin and OVA does not reduce mouse mortality to B16-OVA. [Figure 20] Intratumoral delivery of 86% chitosan did not slow B16 tumor growth or extend mouse survival. [Figure 21] C100 drives STING activation in B16 and MC38 tumor cell lines. [Figure 22] C100 drives STING activation in human cells. [Figure 23] C100 has tumoricidal activity. [Figure 24] Intratumoral delivery of polyglucosamine slows MC38 tumor growth and prolongs survival in mice. [Figure 25] FIG. 1 is a schematic diagram comparing homogeneous and heterogeneous acetyl group distribution in a polyglucosamine backbone. Specific Description of the Invention

[0010] Chitosan and Polyglucosamine "Chitosan" is a linear polysaccharide composed of randomly distributed β(l→4)-linked D-glucosamine (deacetylated units) and N-acetyl-D-glucosamine (acetylated units). Chitosan is typically commercially produced by deacetylation of chitin, a structural component of the exoskeletons of crustaceans (e.g., crabs and shrimp) and the cell walls of fungi. Chitin is at least 90% acetylated. The deacetylation degree (% DD) of chitosan refers to the percentage of deacetylated units (β(l→4)-linked D-glucosamine) in the molecule and may be determined by NMR spectroscopy. Chitosan is otherwise sometimes referred to as "acetylated polyglucosamine." In one embodiment, chitosan (acetylated polyglucosamine) is derived from a synthetic (non-natural) source (e.g., by linking monomeric glucosamine and / or monomeric N-acetyl-D-glucosamine).

[0011] As used herein, "polyglucosamine" refers to a polymer of β(1→4)-linked D-glucosamine that does not contain N-acetyl-D-glucosamine. The term "polyglucosamine" may be used interchangeably with "100% deacetylated chitin" (i.e., chitosan polymers that do not contain acetyl groups).

[0012] As used herein, "acetylated polyglucosamine" refers to a polymer of β(1→4)-linked D-glucosamine containing additional N-acetyl-D-glucosamine groups. The term "acetylated polyglucosamine" may be used interchangeably with "chitosan." Acetylated polyglucosamine may not be derived from chitin. For example, acetylated polyglucosamine or polyglucosamine may be synthetically produced from its monomer subunits (e.g., monomeric glucosamine and / or monomeric N-acetyl-D-glucosamine). The degree of acetylation (%) of acetylated polyglucosamine refers to the proportion of acetylated units (β(1→4)-linked D-glucosamine) in the molecule and may be determined by NMR spectroscopy.

[0013] The polyglucosamine or acetylated polyglucosamine / chitosan may not contain glutamic acid. The acetylated polyglucosamine / chitosan may not be protasan glutamate. The polyglucosamine or acetylated polyglucosamine of the present invention may not form clumps / aggregates. The polyglucosamine or acetylated polyglucosamine of the present invention may not be in the form of microparticles. In one embodiment, the polyglucosamine or acetylated polyglucosamine is in the form of a free chain (e.g., non-aggregated). In one embodiment, the polyglucosamine or acetylated polyglucosamine is positively charged, e.g., in a chain form in the composition. In one embodiment, the polyglucosamine or acetylated polyglucosamine is a chain with a net positive charge. The polyglucosamine or acetylated polyglucosamine may not be crosslinked or conjugated to other molecules, such as antigens or ligands. In one embodiment, the amino group of polyglucosamine or acetylated polyglucosamine may not be covalently bound to other molecules, such as antigens or ligands. Polyglucosamine or acetylated polyglucosamine may not be bound to TLR agonists or surfactants. Such binding of other molecules, such as surfactants or TLR agonists, may neutralize the net positive charge and cause undesirable aggregation.

[0014] In a preferred embodiment, the polyglucosamine or acetylated polyglucosamine is not hydrolyzed.

[0015] In one embodiment according to the first aspect, the acetylated polyglucosamine is 8% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 6% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 5% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 4% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 3% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 2% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 1% or less acetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is 0.5% or less acetylated.

[0016] In one embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is at least 90% deacetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is at least 92% deacetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is at least 95% deacetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is at least 98% deacetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is at least 99% deacetylated. In another embodiment according to the first aspect, the acetylated polyglucosamine is chitosan and is 100% deacetylated.

[0017] According to the second aspect, the acetylated polyglucosamine may be chitosan and at least 10% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 15% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 20% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 38% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 40% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 49% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and at least 50% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 70% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 72% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 80% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 90% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 95% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 98% deacetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is chitosan and is at least 99% deacetylated. In another embodiment according to the second aspect, the polyglucosamine is not acetylated and is 100% deacetylated chitosan.

[0018] In one embodiment according to the second aspect, the acetylated polyglucosamine is no more than 90% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 80% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 60% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 50% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 30% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 20% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 15% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 10% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is no more than 8% acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is 5% or less acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is 2% or less acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is 1% or less acetylated. In another embodiment according to the second aspect, the acetylated polyglucosamine is 0.5% or less acetylated.

[0019] It is preferred to use polyglucosamine or chitosan polymers in which 90% or more of the acetyl groups have been removed, and even more preferred to use polyglucosamine or chitosan in which less than 1% of the glucosamine units are acetylated.

[0020] The N-acetyl-D-glucosamine groups may be distributed in blocks of 3 or more throughout the acetylated polyglucosamine. The N-acetyl-D-glucosamine groups may be distributed in blocks of 4 or more throughout the acetylated polyglucosamine. The N-acetyl-D-glucosamine groups may be distributed in blocks of 5 or more throughout the acetylated polyglucosamine. The N-acetyl-D-glucosamine groups may be distributed in blocks of 10 or more throughout the acetylated polyglucosamine.

[0021] The N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine containing at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units).

[0022] Those skilled in the art will recognize that the block pattern may not be uniform, that blocks of various lengths may be present in a given acetylated polyglucosamine polymer, and / or that the distribution of block patterns may vary among different acetylated polyglucosamine polymers in the composition. In one embodiment, the block length of N-acetyl-D-glucosamine groups or β(1→4)-linked D-glucosamine units (i.e., non-acetylated units) may refer to the majority (e.g., greater than 50%) of the blockwise distribution. Alternatively, the block length of N-acetyl-D-glucosamine groups or β(l→4)-linked D-glucosamine units (i.e., non-acetylated units) may refer to the average of a block-wise distribution (e.g., some blocks of β(l→4)-linked D-glucosamine units (i.e., non-acetylated units) may be longer than others, and some blocks of β(l→4)-linked D-glucosamine units (i.e., non-acetylated units) may be interrupted / separated by one or more N-acetyl-D-glucosamine groups).

[0023] In one embodiment according to the first aspect, the acetylated polyglucosamine contains 8% or less acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine containing at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the first aspect, the acetylated polyglucosamine contains 5% or less acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine containing at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the first aspect, the acetylated polyglucosamine contains 2% or less acetylation, and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine containing at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(l→4)-linked D-glucosamine units (i.e., non-acetylated units).

[0024] In one embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 90% acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 20% acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 50% acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 80% acetylation and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units). In another embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 90% acetylation, and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(1→4)-linked D-glucosamine units (i.e., non-acetylated units).In another embodiment according to the second aspect, the acetylated polyglucosamine comprises up to 95% acetylation, and the N-acetyl-D-glucosamine groups may be distributed in blocks such that there are blocks in the acetylated polyglucosamine comprising at least 2, 3, 4, 5, 10, 15, 20, 40, or 50 consecutive β(l→4)-linked D-glucosamine units (i.e., non-acetylated units).

[0025] In embodiments comprising distributed blocks of β(1→4)-linked D-glucosamine units, the block distribution may be across substantially all of the acetylated polyglucosamine molecules in the acetylated polyglucosamine population. The pattern and / or size of the distribution of the blocks of β(1→4)-linked D-glucosamine units may be heterogeneous. In one embodiment, the acetyl groups are clustered in blocks (i.e., not uniformly / homogenously distributed) throughout the polyglucosamine backbone.

[0026] The polyglucosamine or acetylated polyglucosamine may have a molecular weight of at least about 100 kDa. In another embodiment, the polyglucosamine or acetylated polyglucosamine may have a molecular weight of at least about 115 kDa. In one embodiment, the polyglucosamine or acetylated polyglucosamine may have a molecular weight of about 100 to about 500 kDa. In one embodiment, the polyglucosamine or acetylated polyglucosamine may have a molecular weight of about 100 to about 1000 kDa. In another embodiment, the polyglucosamine or acetylated polyglucosamine may have a molecular weight of about 115 to about 1000 kDa. References to the molecular weight of polyglucosamine or acetylated polyglucosamine are intended to refer to the average molecular weight of the composition of polyglucosamine or acetylated polyglucosamine polymers.

[0027] In one embodiment, a mixture of polyglucosamine and acetylated polyglucosamine may be administered / used.

[0028] In one embodiment, the adjuvant is administered without the antigen (e.g., predefined and purified). The antigen may be combined with the adjuvant, not administered simultaneously with the adjuvant or sequentially with the adjuvant. Alternatively, the adjuvant may induce endogenous antigen release upon injection.

[0029] gun The cancer may be a solid cancer. The solid cancer may be selected from sarcoma, carcinoma, and lymphoma. In one embodiment, the solid cancer comprises melanoma. In another embodiment, the solid cancer comprises colon cancer. In another embodiment, the cancer comprises a cancer selected from the group including CNS tumors, breast cancer, leukemia, lung cancer, melanoma, prostate, AML, esophageal, ovarian, bladder, glioma, and multiple myeloma.

[0030] Antitumor antigens The anti-tumor antigen may include any known antigen for cancer (e.g., solid cancer). Antigens for cancer include TAA (tumor-associated antigen) peptide mix, P10s-PADRE, PR1 peptide, neoantigen, MUC-1, pBCAR3 peptide, MAGE-A3, MAG-Tn3, PRAME, neoantigen, Bcl-XL, NY-ES0-1, WT1 peptide, GAA / TT-peptide, NY-ESO-1b, URLCl0-177, MAGE-3.1, gp100, Pros. spec peptide, ras peptide, THERATOPE, Globo H-GM2, and sialyl Lewis. aThe antigen may be selected from the group of antigens including (CA19-9), MUC-2-KLH, NY-ESO-1, CDX-1401, CDX-1307, tumor lysate, CDX-1401, HER2 peptide, ALVAC-NY-ESO-1, CMB305, IDC-0305, MB305, SVN53-67-KLH, PR1 peptide, MART-1, and rsPSMA; or a combination thereof. Suitable antigens for such cancers are disclosed in Schijns et al. (2020 Immunological Reviews, DOI: 10.1111 / imr.12889), which is incorporated herein by reference. In one embodiment, the antigen for cancer is one or more tumor-associated antigens. In one embodiment, the antigen for cancer is a neoantigen.

[0031] Neoantigens may be multiple antigens specific to a patient's cancer. Those skilled in the art will recognize that neoantigens are a subset of tumor-specific antigens generated by specific nonsynonymous mutations and other genetic polymorphisms in the tumor genome, presented by major histocompatibility complex (MHC) molecules, and recognized by endogenous T cells. The most well-studied class of neoantigens are those derived from single nucleotide polymorphisms (SNVs), which cause nonsynonymous changes in proteins and may subsequently trigger antigen-specific T cell responses against the tumor. These may be advantageous compared to other classes of tumor antigens because they are not expressed in normal tissues. The neoantigen may be a neoantigen of metastatic melanoma. In another embodiment, the neoantigen may be a neoantigen of lung cancer. In another embodiment, the neoantigen is from a CNS tumor, breast cancer, leukemia, lung cancer, melanoma, prostate, AML, esophageal, ovarian, bladder, glioma, or multiple myeloma.

[0032] In one embodiment, antigens for ovarian cancer may include or be selected from the group of antigens including GM2, globo H, sTn, TF, and Ley. In one embodiment, antigens for prostate cancer may include or be selected from the group of antigens including GM2, Tn, sTn, TF, and Ley. In one embodiment, antigens for breast cancer may include or be selected from the group of antigens including GM2, globo H, Tn, sTn, TF, and Ley. In one embodiment, antigens for small cell lung cancer may include or be selected from the group of antigens including GM2, fucosyl GM1, polysialic acid, globo H, and sialyl Lea. In one embodiment, antigens for sarcoma may include or be selected from the group of antigens including GM2, GD2, and GD3. In one embodiment, antigens for neuroblastoma may include or be selected from the group of antigens including GM2, GD2, GD3, and polysialic acid. In one embodiment, the antigens for melanoma may include all or a selection of the group of antigens including GM2, GD2 and GD3.

[0033] In one embodiment, the antigen for CNS tumors may comprise a TAA peptide mix. In one embodiment, the antigen for breast cancer may comprise one or more of the group of antigens comprising P10s-PADRE, MAG-Tn3, THERATOPE, and HER2 peptide. In one embodiment, the antigen for leukemia may comprise PR1 peptide. In one embodiment, the antigen for lung cancer may comprise one or more of the group of antigens comprising MUC-1, PRAME, NY-ESO-1b, ras peptide, and CMB305. In one embodiment, the antigen for melanoma may comprise one or more of the group of antigens comprising pBCAR3 peptide, MAGE-A3, NY-ESO-1, MAGE-3.1, gp100, NY-ESO-1, CDX-1401, CDX-1401, and MART-1. In one embodiment, the antigen for prostate cancer may comprise one or more of the group of antigens comprising Bcl-XL, Pros.spec peptide, sialyl Lewis.a (CA19-9), MUC-2-KLH, and rsPSMA. In one embodiment, the antigen for AML may comprise WT1 peptide. In one embodiment, the antigen for esophageal cancer may comprise URLC10-177. In one embodiment, the antigen for ovarian cancer may comprise one or more of the group of antigens including Globo H-GM2 and ALVAC-NY-ESO-1. In one embodiment, the antigen for bladder cancer may comprise CDX-1307. In one embodiment, the antigen for glioma may comprise GAA / TT-peptide and / or tumor lysate. In one embodiment, the antigen for multiple myeloma may comprise SVN53-67-KLH. In one embodiment, the antigen for solid tumors may comprise neoantigens and / or ras peptides. In one embodiment, the antigen may comprise tumor lysate, tumor extract, or killed tumor cells.

[0034] Combinations and dosages of antitumor antigens and adjuvants Those skilled in the art will be familiar with the routes of administration and dosages of antigens and adjuvants. For example, administration may be subcutaneous, intramuscular, intradermal, intraperitoneal, or intravenous. According to the first aspect, the adjuvant and / or anti-tumor antigen may be delivered or prepared to be delivered intravenously, subcutaneously, intradermal, intraperitoneally, or intramuscularly. Preferably, the adjuvant and / or anti-tumor antigen is delivered or prepared to be delivered subcutaneously or intramuscularly. In another embodiment according to the first aspect, administration of the adjuvant and / or anti-tumor antigen may be intratumoral and / or peritumoral. In one embodiment, administration of the adjuvant and / or antigen is subcutaneous, intramuscular, or intratumoral.

[0035] According to a first aspect, the adjuvant may be administered before, simultaneously with, or after the anti-tumor antigen. The adjuvant may be formulated separately from or together with the anti-tumor antigen (i.e., delivered in the same dose or in separate doses).

[0036] The adjuvant and anti-tumor antigen may be formulated together or separately in a pharmaceutically acceptable carrier.

[0037] The dose of the adjuvant and / or anti-tumor antigen may be sufficient to provide an immunogenic effect in a subject. In one embodiment, the dose of the adjuvant is sufficient to activate cGAS-STING-dependent innate immune signals in tumors. The dose of the adjuvant may be sufficient to activate IFNAR-dependent Thl responses and antigen-specific IgG2c production. Multiple doses may be administered until a therapeutic / immunogenic effect (e.g., induction of a sufficient immune response in a subject) is observed. In one embodiment, the administration of the anti-cancer antigen and adjuvant may include a prime-boost regimen (i.e., an initial administration followed by one or more additional administrations).

[0038] The anti-tumor antigens and adjuvants may be used as vaccines in combination with other therapeutically or prophylactically active ingredients.

[0039] The other therapeutically or prophylactically active ingredient may comprise or consist of CpG (CpG oligodeoxynucleotides (or CpG ODNs), which are short, single-stranded synthetic DNA molecules). In another embodiment, the other therapeutically or prophylactically active ingredient may comprise or consist of other agonists of toll-like receptors, nod-like receptors, C-type lectin receptors, AIM2-like receptors, or other pathogen recognition receptors, or a combination of pathogen recognition receptor agonists.

[0040] Intratumoral / peritumoral administration of polyglucosamine or chitosan into solid tumors According to a second aspect, intratumoral / peritumoral administration of polyglucosamine or chitosan to a solid tumor in a subject may comprise administration of a therapeutically effective amount of polyglucosamine or chitosan, which may be sufficient to activate cGAS-STING-dependent innate immune signaling in the tumor, and optionally activate an IFNAR-dependent Th1 response and antigen-specific IgG2c production.

[0041] Polyglucosamine or chitosan may be administered intratumorally and / or peritumorally by injection. In a preferred embodiment, administration is intratumorally. However, peritumoral administration may be advantageous when necrotic lesions are present in the center of the tumor mass.

[0042] Polyglucosamine or chitosan may be administered in an amount sufficient to produce a therapeutic effect. Polyglucosamine or chitosan may be administered in a single dose or multiple doses. Repeated doses may be administered until a therapeutic effect (e.g., reduction in tumor size, partial or complete tumor cell death) is observed. In embodiments in which polyglucosamine or chitosan is administered repeatedly, the time between doses may be 2 to 4 weeks. Repeated doses may be daily (e.g., up to one week), on consecutive days, or every three days (e.g., up to one month). Repeated doses may be provided for an initial period of one week to one month, and then less regularly for a period of one month or more. In one embodiment, repeated doses are provided about one, two, or three times per week. In another embodiment, there is at least one week between doses. In another embodiment, there is at least two weeks between doses.

[0043] Polyglucosamine or chitosan may be administered / used alone or in combination with another therapeutic agent. Polyglucosamine or chitosan may be administered / used in combination with a checkpoint inhibitor for the treatment of cancer. Thus, in one embodiment, the method or use according to the present invention may further comprise the administration of a checkpoint inhibitor.

[0044] Other therapeutically or prophylactically active ingredients may additionally or alternatively include CpG (CpG oligodeoxynucleotide (or CpG ODN) which is a short, single-stranded synthetic DNA molecule), MPL or other pathogen recognition receptor agonists, or a combination of pathogen recognition receptor agonists, or may consist of CpG (CpG oligodeoxynucleotide (or CpG ODN) which is a short, single-stranded synthetic DNA molecule), MPL or other pathogen recognition receptor agonists, or a combination of pathogen recognition receptor agonists.

[0045] In one embodiment, the checkpoint inhibitor is formulated and administered separately from the polyglucosamine or chitosan, e.g., the polyglucosamine or chitosan may be administered intratumorally and the checkpoint inhibitor may be administered systemically.

[0046] The checkpoint inhibitor may be selected from an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA-4 antibody, an anti-TIGIT antibody, and a CD40 agonist antibody. In one embodiment, the checkpoint inhibitor may be selected from nivolumab, pembrolizumab, atezolizumab, avelumab, and tiragolumab. In one embodiment, the checkpoint inhibitor may be an antibody that targets the same protein or pathway as any of the antibodies selected from nivolumab, pembrolizumab, atezolizumab, avelumab, and tiragolumab. In one embodiment, the checkpoint inhibitor may be an antibody that competes for binding with any of the antibodies selected from nivolumab, pembrolizumab, atezolizumab, avelumab, and tiragolumab.

[0047] Polyglucosamine or chitosan may be administered / used in combination with an adjuvant. For example, an adjuvant that induces a CD8 response may be administered before, during, or after the administration of polyglucosamine or chitosan. Polyglucosamine or chitosan may be formulated together with an adjuvant.

[0048] The adjuvant may be an immunostimulant. The adjuvant may include an agonist of a pathogen recognition receptor that enhances cellular immunity (e.g., a toll-like receptor (TLR) agonist (e.g., CpG (TLR9), MPL (TLR4)), an NLR agonist, a C-type lectin receptor (CLR) agonist, or an AIM2-like receptor or RIG I agonist). The agonist may be a particulate adjuvant that promotes cellular immunity, such as nanoparticles, CAF01, IC31, AS01, attenuated viruses (e.g., measles vaccines), or attenuated bacteria (e.g., BCG vaccines).

[0049] Polyglucosamine or chitosan may be administered / used in combination with a cytokine (eg, GM-CSF, IL-12 or TNF-α).

[0050] The polyglucosamine or chitosan may be provided in a carrier for intratumoral / peritumoral administration. The carrier may be an aqueous carrier. In one embodiment, the carrier is a pharmaceutically acceptable carrier.

[0051] subject The subject may be a mammal. In one embodiment, the subject is a human. In another embodiment, the subject may be a livestock or farm animal. The subject may have a solid tumor cancer, such as melanoma. The subject may have a sarcoma, carcinoma, or lymphoma.

[0052] Other Aspects According to another aspect of the present invention, there is provided an adjuvant for use in combination with an anti-tumor antigen for immunotherapy of cancer in a subject, the adjuvant comprising polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, the N-acetyl-D-glucosamine groups being distributed in two or more blocks throughout the acetylated polyglucosamine.

[0053] According to another aspect of the present invention, there is provided a composition comprising an adjuvant and an anti-tumor antigen, wherein the adjuvant comprises polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, the N-acetyl-D-glucosamine groups being distributed in two or more blocks in the acetylated polyglucosamine.

[0054] The composition may comprise a pharmaceutically acceptable carrier. The composition may be aseptic / sterile. The composition may be immunogenic in a mammal, for example, a human.

[0055] According to another aspect of the invention, a composition comprising: i) an adjuvant; and ii) Antitumor antigens A kit comprising: Kits are provided in which the adjuvant comprises polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, the N-acetyl-D-glucosamine groups being distributed in two or more blocks in the acetylated polyglucosamine.

[0056] The adjuvant and anti-tumor antigen of the kit may be formulated separately in pharmaceutically acceptable carriers.

[0057] According to another aspect of the present invention, there is provided the use of polyglucosamine or chitosan in the immunotherapy of solid cancer in a subject.

[0058] Polyglucosamine or chitosan may be used as an active therapeutic agent (e.g., as the sole therapeutic agent or in combination with a checkpoint inhibitor). In one embodiment, the use of polyglucosamine or chitosan as a therapeutic agent may not be in combination with a vaccine or antigen (such as an anti-tumor vaccine / antigen).

[0059] Immunotherapy for solid tumor cancers may include administering polyglucosamine or chitosan intratumorally and / or peritumorally. In particular, immunotherapeutic use may be by intratumoral and / or peritumoral administration.

[0060] According to another aspect of the present invention, there is provided a composition comprising polyglucosamine or acetylated polyglucosamine, said composition formulated for intratumoral and / or peritumoral administration.

[0061] The acetylated polyglucosamine may contain up to 10% N-acetyl-D-glucosamine groups, said N-acetyl-D-glucosamine groups being distributed in two or more blocks in the acetylated polyglucosamine.

[0062] The composition may include one or more pharmaceutically acceptable excipients.

[0063] Reference herein to "intratumoral administration" is intended to refer to direct injection into a solid tumor. Reference herein to "peritumoral administration" is intended to refer to direct injection into the space or tissue surrounding a solid tumor.

[0064] Reference herein to a "solid tumor" is intended to refer to an abnormal mass or growth of tissue in the body of a subject. A solid tumor may be benign (not cancerous) or malignant (cancer). In one embodiment, the solid tumor is malignant.

[0065] Reference to "immunotherapy" herein is intended to refer to the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to induce or amplify an immune response are classified as activating immunotherapies, while immunotherapies that decrease or suppress are classified as suppressing immunotherapies. The immunotherapeutic method or use of the present invention herein may be an activating immunotherapy designed to induce or amplify an immune response against cancer cells or components thereof.

[0066] Checkpoint inhibitor therapy is a type of cancer immunotherapy that targets immune checkpoints—key regulators of the immune system that stimulate or suppress immune activity and can be used by tumors to defend themselves against immune attack. Checkpoint therapy can block inhibitory checkpoints, restoring immune system function.

[0067] The term "immunogenic" as applied to the present invention means capable of eliciting an immune response in a human or animal body. The immune response may be protective. The term "protective" means preventing cancer, reducing the risk of cancer, reducing the progression of cancer, reducing the severity of cancer, curing cancer, alleviating symptoms, or reducing the severity of cancer or cancer symptoms.

[0068] "Treatment" means curing cancer, alleviating the symptoms, or reducing the severity of cancer or cancer symptoms.

[0069] Reference to a "homogeneous" distribution is understood to mean that the acetyl groups are evenly distributed throughout the polyglucosamine backbone. Reference to a "heterogeneous" distribution is understood to mean that the acetyl groups are clustered together.

[0070] Those skilled in the art will appreciate that any feature of one embodiment or aspect of the invention may, where appropriate, be applicable to other embodiments or aspects of the invention.

[0071] Embodiments of the invention will now be described in more detail, by way of example only, with reference to the accompanying drawings, in which:

[0072] Figure 1. BMDCs phagocytose C100 and Protasan.BMDCs were incubated with FITC-labeled C100 and Protasan CL213 (green) (5 μg / ml) for 6 hours. Afterwards, cells were washed, and mitochondria were stained with Mitotracker Red (red) and nuclei with Hoechst 33342 (blue). Cells were analyzed by confocal microscopy. Results are representative of two independent experiments.

[0073] Figure 2. Highly deacetylated chitosan polymer enhances mitochondrial reactive oxygen species production. (ab) Analysis of mtROS production in single viable BMDCs treated with the indicated concentrations of chitin-derived polymer (5 μg / mL) for 1.5 hours or rotenone (5 μM) for 6 hours. (a) FSC-W vs. MitoSOX. (b) Unit area vs. MitoSOx. Data are representative of four independent experiments. (ce) Analysis of mtROS production in single viable BMDCs treated with homogeneous and heterogeneous 83% deacetylated chitosan polymer (8 μg / mL) for 1.5 hours or rotenone (5 μM) for 6 hours. (c) FSC-W vs. MitoSOX. (d) Unit area vs. MitoSOx. (e) Combined data from two independent experiments were analyzed by one-way ANOVA. * p<0.05 ** p<0.01. MFI = mean fluorescence intensity.

[0074] Figure 3. Highly deacetylated chitosan polymer drives mitochondrial stress in BMDCs. (ab) Analysis of mtROS production in single viable BMDCs treated with the indicated concentrations of chitin-derived polymers (2, 4, or 8 μg / mL) for 1.5 h or with rotenone (5 μM) for 6 h. (a) FSC-W vs. MitoSOX. (b) Unit area vs. MitoSOx. Numbers correspond to the mean fluorescence intensity. Data are representative of four independent experiments.

[0075] Figure 4. Highly deacetylated chitosan polymers are toxic to BMDCs. BMDCs were treated with various deacetylated chitin-derived polymers (5 μg / mL) for 2 h or rotenone (5 μM) for 6 h. (a) Flow cytometry analysis of cell viability. Data are representative of four independent experiments. MFI = mean fluorescence intensity.

[0076] Figure 5. The degree of polymer deacetylation determines the extent of type I IFN production and IFNAR-dependent DC maturation. (a) WT and ifnar - / - BMDCs from mice were treated with C90, C100, or protasan (2, 4, or 8 μg / mL), CpG (4 μg / mL), or LPS (10 ng / mL) for 24 hours. After this period, cells were harvested and stained for flow cytometry. BMDCs were isolated from single, viable CD11c+, MHCcII+, and MHCcII+ cells. Hi Cells were gated as CD80 and CD86 expression and analyzed. Representative histograms and mean fluorescence intensity values ​​for CD80 and CD86 are shown. Data are representative of three independent experiments. c) ELISA analysis of IFN-β secretion in supernatants from BMDCs stimulated for 24 hours with the indicated concentrations of homogeneous and heterogeneous chitosan polymers or CpG (4 μg / mL). Results are presented as the mean ± SD of technical triplicates and represent data from three independent experiments.

[0077] Figure 6. Chitin-derived polymer-induced inflammasome activation by BMDCs depends on the degree and distribution of deacetylation. (a) BMDCs were stimulated with medium, CpG (4 μg / mL), or LPS (10 ng / mL) alone, or with chitin-derived polymers (0.8–6.25 μg / mL) or alum (10 ng / mL). IL-Iβ levels were measured in the supernatant after 24 h. Results are expressed as the mean ± SD of technical triplicates and are representative of three independent experiments. Statistical analysis was performed by one-way ANOVA with Dunnett's multiple comparison test (CpG vs. CpG + chitin-derived polymer). *** p<0.001 ****p<0.0001. (b) BMDCs were stimulated with medium or LPS (10 μg / mL) alone or in combination with homogeneous or heterogeneous chitosan polymer (6.25 μg / mL) or alum (10 μg / mL). IL-1β levels were measured in the supernatants after 24 hours. Results are expressed as the mean ± SD of technical triplicates and are representative of three independent experiments. (a) Statistical analysis was performed by one-way ANOVA with Dunnett's multiple comparison test. (a) CpG vs. CpG + chitin-derived polymer. (b) LPS vs. LPS + chitin-derived polymer. p **** <0.0001.

[0078] Figure 7. C100 induces mitochondrial ROS, DC maturation, and inflammasome activation across a broad molecular weight range. (a) BMDCs were treated with chitin-derived polymer (8 μg / mL) for 1.5 hours or rotenone (5 μM) for 6 hours. mtROS was measured for single live cells. + The percentage of cells and MitoSOX fluorescence were analyzed. Data from two independent experiments were combined and analyzed by one-way ANOVA with Tukey's multiple comparison test. MFI = mean fluorescence intensity (b). BMDCs were treated with C90, C100, or protasan (2, 4, or 8 μg / mL), CpG (4 μg / mL), or LPS (10 ng / mL) for 24 hours. After this period, cells were harvested and stained for flow cytometry. BMDCs were identified as single, viable CD11c+, MHCcIIm+, and CD11c+. Hi Cells were gated as CD80 and CD86 and analyzed for CD80 and CD86 expression. Figures show representative histograms and MFI values ​​for CD80 and CD86. Data are representative of four independent experiments. (d) BMDCs were stimulated with medium or LPS (10 μg / mL) alone or in combination with chitin-derived polymer (1.56 μg / mL) or alum (10 μg / mL). IL-Iβ levels were measured in the supernatant after 24 hours. Results are presented as the mean ± SD of technical triplicates and are representative of three independent experiments. Statistical analysis was performed by two-way ANOVA with Sidak's multiple comparison test.

[0079] Figure 8. C100 of various molecular weights is a more potent inducer of mtROS and cell death than less deacylated chitosan polymers.Wild-type mouse BMDCs were treated with 8 μg / mL chitin-derived polymers for 2 hours or 1 μM rotenone for 6 hours. Single live cells were analyzed for MitoSOX fluorescence. (a) Gating strategy. (b) Percentage of mtROS+ cells in single live cells. (C) Histogram of MitoSOX fluorescence in live cells. Values ​​on the graph correspond to mean fluorescence intensity (MFI). (d) Overlaid histogram of polyglucosamine polymers of various molecular weights. (e) Percentage of cell death in single cells. Statistical analysis was determined by two-way ANOVA.

[0080] Figure 9. Highly deactylated chitosan polymers are STING agonists. (a-b) Wild-type and sting cells stimulated with the indicated concentrations of chitin-derived polymers, CpG (4 μg / mL), or LPS (10 ng / mL) for 24 hours. - / - ELISA analysis of (b) IFN-β and (c) CXCL10 secretion in the supernatants of BMDCs. Results are expressed as the mean ± SD of technical triplicates and are representative of data from three independent experiments. Statistical significance was determined using an unpaired, two-tailed Student's t-test with the Holm-Sidak method for multiple comparisons. *** p<0.001. (c) Wild-type mice and sting - / - Mouse-derived BMDCs were treated with chitin-derived polymers (8 μg / mL) for 24 hours or LPS (10 ng / mL) for 2 hours. mRNA levels were calculated by qPCR for Ifna and Ifnb relative to β-actin and S18. Data show mRNA levels of technical triplicates for β-actin and are representative of three independent experiments. Statistical significance was determined using an unpaired, two-tailed Student's t-test with the Holm-Sidak method for multiple comparisons. **** p<0.0001.

[0081] Figure 10. Low-dose ethidium bromide treatment depletes mtDNA in BMDCs.(a) Schematic of the experiment used to deplete mitochondrial DNA (mtDNA) in BMDCs (see Materials and Methods for details). (b) Flow cytometry analysis of ethidium bromide toxicity in single cells at day 11 (data representative of two independent experiments). (c) Combined toxicity data from two independent experiments were analyzed with an unpaired, two-tailed Student's t-test. * *P<0.05. (d) On day 10, relative total mtDNA abundance was quantified by qPCR using primers specific for the mitochondrial D-loop region (dloop) or a region of mtDNA not inserted into nuclear DNA (non-NUMT), and primers specific for nuclear DNA (Tert, B2m). Statistical analysis of technical triplicates was performed by unpaired two-tailed Student's t-test. Data are representative of four independent experiments. *** p<0.001; **** p<0.0001.

[0082] Figure 11. C100-induced transcription of ifna and ifnb mRNAs does not require mtDNA. Wild type (WT) and STING - / - Bone marrow precursors were cultured as normal to generate BMDCs (control BMDCs) or cultured in low-dose ethidium bromide to deplete mtDNA as described in Figure 10. Cells were then treated with chitin-derived polymer (5 μg / mL) for 24 hours or with CpG (4 μg / mL) or LPS (10 ng / mL) for 3 hours. (a) Ifna and (b) Ifnb mRNA levels were calculated by qPCR for β-actin and S18. Results represent mRNA levels in technical triplicates relative to β-actin and are representative of five independent experiments. Statistical analysis was performed by unpaired two-tailed Student's t-test using the Holm-Sidak method for multiple comparisons. ** P < 0.01; *** P < 0.001; **** P<0.0001.

[0083] Figure 12. C100 drives robust nuclear DNA fragmentation.BMDCs were treated with 5 μg / mL chitin-derived polymer for 9 hours. As a control, cells were either left untreated (medium) or stimulated with 50 μM etoposide for 24 hours. DNA fragmentation was monitored using the BrdUTP / alex488-anti-BrdUTP TUNEL labeling system. The figure shows the ratio of DNA fragmentation (BrdU-Alexa488+) to total DNA (PI+) in a single cell.

[0084] Figure 13. Protosan and C90 do not cause DNA damage in BMDCs. BMDCs were treated with 5 μg / mL protosan, C90, or C100 for the indicated times, or with 100 pM etoposide for 24 hours. (a) DNA fragmentation as a percentage of total DNA in single cells. (b) DNA fragmentation as a percentage of total DNA in single, live cells. (c) BMDCs were stimulated with C100, C90, or protosan for the indicated times and then lysed to determine p-H2A.x expression levels. Densitometry readings of p-H2A.x expression levels relative to β-actin compared to medium treatment alone.

[0085] Figure 14. Ethidium bromide and C100 treatment drive synergistic DNA damage.(a) BMDCs were cultured as standard or with low-dose ethidium bromide (see M&M for detailed description of the culture protocol) and, on day 10, stimulated with C100 (8 μg / mL) for 8 or 16 hours or etoposide (100 μM) for 16 hours. Cells were then lysed and blotted for expression of phosphorylated H2A.x. B-actin was used as a loading control. (b) Corresponding densitometry expression levels of p-H2A.x relative to B-actin, compared with media treatment alone. Data are representative of two independent experiments. (c) BMDCs were cultured as standard (control BMDCs) or in low-dose ethidium bromide (see M&M for detailed description of the culture protocol) and, on day 10, stimulated with C100 (8 μg / mL) for 8 or 16 hours or etoposide (100 μM) for 16 hours. Cells were harvested and stained for analysis of DNA fragmentation by FACS. The extent of DNA fragmentation was measured as a percentage of total DNA in (d) single viable cells and (e) single cells.

[0086] Figure 15. Intratumoral delivery of C100 significantly suppresses tumor growth and promotes survival. 3.5×10 5 B16 melanoma cells were injected subcutaneously into mice. Tumors grew to 75 mm 3 At this time, PBS or C100 (200 μg) was injected, and this was repeated 3 days later on day 4. A) Tumor growth rates at the challenge site were expressed as mean tumor volume ± SEM. A two-tailed paired t-test was used to determine statistical significance between PBS- and C100-treated mice ( * p<.05, ** p<0.01, *** p<0.001). Spider plot of individual tumor growth. C) Kaplan-Meier survival analysis of challenged mice. Mantel-Cox test was used to determine statistical significance between PBS-treated and C100-treated mice ( * p<.05, ** p<0.01, and *** p<0.001).

[0087] Figure 16. C100 and C90 drive potent antigen-specific antitumor immunity in a preventative setting. On days 0 and 7, PBS, OVA peptide (10 μg) alone, C100 ( 200μg ) + OVA peptide (10 μg), C90 ( 200μg Mice were immunized with Protasan (200 μg) + OVA peptide (10 μg), or Protasan (200 μg) + OVA peptide (10 μg), and then immunized with 3.5 × 10 5 Mice were challenged subcutaneously with B16-OVA tumor cells. A) Initial tumor growth rates (shown as mean tumor volume ± SEM) at the challenge site in tumor-bearing mice before the humane endpoint. B) Spider plots of individual tumor growth. The percentage of mice that exhibited complete protection (CP) is also plotted. C) Percentage of mice bearing tumors at the challenge site after tumor implantation. C) Kaplan-Meier survival analysis of challenged mice.

[0088] Figure 17. Intratumoral delivery of C100, C90, and Protasan inhibits tumor growth and promotes prolonged survival. 3.5 x 10 for mouse 5 B16 melanoma cells were injected subcutaneously. 3 Once tumors reached 100 mg / kg / day, they were injected with PBS, C100 (200 μg), C90 (200 μg), or Protasan (200 μg), and this was repeated 3 days later on day 4. A) Tumor growth rate at the challenge site is expressed as mean tumor volume. B) Spider plot of individual tumor growth. C) Kaplan-Meier survival analysis of challenged mice (Mantel-Cox test was used to determine statistical significance between PBS and treated mice (ns = not significant). * p<.05, ** p<0.01, *** p<0.001).

[0089] Figure 18. Enhancement of Th1 immune responses to the TB antigen H56 by subcutaneous administration requires complete deacetylation of chitin. On day 0, C57BL / 6 mice were subcutaneously immunized with PBS or H56 (0.5 μg) alone or in combination with a chitin-derived polymer (200 μg / mouse). On day 14, mice were immunized with the same formulations, and on day 21, spleens and inguinal lymph nodes were harvested. (a) Spleen cells (2 × 10 6 cells / mL) and (b) inguinal lymph nodes (l × 10 6Cells / mL) were restimulated ex vivo with either medium or H56 (2 μg / mL or 10 μg / mL). IFN-γ levels were measured in the supernatants after 72 hours by ELISA. Data represent the mean + SD of five mice per experimental group. Statistical analysis was determined by one-way ANOVA. Antigen alone vs. antigen + chitin-derived polymer. p **** <0.0001.

[0090] Figure 19. Prophylactic immunization with 86% deacetylated chitin and OVA does not reduce mouse mortality to B16-OVA. On day 0, C57BL / 6 mice were immunized intramuscularly with PBS or OVA alone or in combination with a chitin-derived polymer (200 μg / mouse). 5 Mice were subcutaneously inoculated with B16 melanoma cells. (a) Schematic diagram of the experimental design. Tumor growth rates at the challenge site were expressed as mean tumor volume. A two-tailed unpaired t-test was used to determine statistical significance between PBS-treated and chitosan-treated mice ( * p<.05, ** p<0.01, *** p<0.001). (c) Spider plot of individual tumor growth. (d) Kaplan-Meier survival analysis of challenged mice (Mantel-Cox test was used to determine statistical significance between PBS-treated and chitosan-treated mice ( ** p<0.01).

[0091] Figure 20. Intratumoral delivery of 86% chitosan does not delay B16 tumor growth or extend mouse survival. 3.5×10 5 B16 melanoma cells were injected subcutaneously into mice. Tumors grew to 75 mm 3 At the time of tumor growth, 30 μL of PBS or chitin-derived polymer (200 μg) was injected into the tumor. Three days later, the tumor was injected as before. (a) Schematic of the experimental design. (b) Tumor growth rate at the challenge site was expressed as mean tumor volume. A two-tailed unpaired t-test was used to determine statistical significance between PBS-treated and chitosan-treated mice ( * p<.05, ** p<0.01, and ***p<0.001). (c) Spider plot of individual tumor growth. (d) Kaplan-Meier survival analysis of challenged mice. Mantel-Cox test was used to determine statistical significance between PBS-treated and chitosan-treated mice. ** p<0.01).

[0092] Figure 21. C100 drives STING activation in B16 and MC38 tumor cell lines. (a) B16 and (b) MC38 (1 × 10 6 Cells (100 μg / mL) were stimulated with DMXAA (10 μg / mL), C100 (10 μg / mL), or 2'3cGAMP (10 μM) for 20 hours. Cells were lysed and STING and β-actin levels were monitored by immunoblotting.

[0093] Figure 22. C100 drives STING activation in human cells. (a) PMA differentiated THP-1 cells (1 × 10 6 Cells (100 μg / mL) were stimulated with C100 (10 μg / mL) or 2'3cGAMP (10 μM) for 16 or 20 hours. Cells were lysed and STING and β-actin levels were monitored by immunoblotting.

[0094] Figure 23. C100 has tumoricidal activity (a) B16 cells (1 × 10) stimulated with C100 (40 μg / mL), DMXAA (10 μg / mL), or CpG (4 μg / mL) for 20 hours. 6 cells / mL) mortality rate (%).

[0095] Figure 24. Intratumoral delivery of polyglucosamine slows MC38 tumor growth and extends mouse survival. 5×10 5 B16 melanoma cells were injected subcutaneously into mice. Tumors grew to 50 mm 3 At the time of reaching 100 μg / mL, 30 μL of PBS or chitin-derived polymer (100 μg) was injected into the tumor. Three days later, the tumor was injected as before. The tumor growth rate at the challenge site was expressed as the mean tumor volume. A two-tailed unpaired t-test was used to determine statistical significance between PBS-treated and chitosan-treated mice ( * p<.05, ** p<0.01, and ***p<0.001). Spider plot of individual tumor growth. Kaplan-Meier survival analysis of challenged mice (Mantel-Cox test was used to determine statistical significance between PBS-treated and chitosan-treated mice ( ** p<0.01).

[0096] Figure 25: Schematic diagram comparing homogeneous and heterogeneous acetyl group distribution in the polyglucosamine backbone. Homogeneous distribution provides acetyl groups that are evenly distributed across the polyglucosamine backbone. Heterogeneous distribution means that the acetyl groups are clustered together.

[0097] Note: Throughout this document, polyglucosamine may be referred to as 100% viscosan / C100. [Example]

[0098] Example 1. Deacetylation of chitin-derived polymers regulates reactive oxygen species-dependent cGAS-STING and NLRP3 inflammasome activation.

[0099] overview Chitosan, a cationic polysaccharide, has been evaluated as an adjuvant due to its biocompatibility and biodegradability. This polysaccharide can enhance antibody responses and cell-mediated immunity after vaccination via injection or mucosal routes. However, the optimal polymer characteristics for dendritic cell (DC) activation and induction of antigen-specific cellular immune responses remain to be determined. Here, we demonstrate that only highly deacetylated polymers enhance mitochondrial ROS generation, leading to type I IFN-induced cGAS-STING induction. Furthermore, the ability of polymers to activate the NLRP3 inflammasome strictly depends on the degree and pattern of deacetylation and mitochondrial ROS generation. While polymers with a degree of deacetylation (DDA) below 80% are poor adjuvants, fully deacetylated "polyglucosamine" polymers are the most effective vaccine adjuvants. Furthermore, this polyglucosamine polymer enhanced antigen-specific Th1 responses in an NLRP3- and STING-type I IFN-dependent manner. Overall, these results indicate that the degree of deacetylation of chitin-derived polymers and the control of mitochondrial ROS are important determinants of their immune-enhancing properties.

[0100] material and method:

[0101] Cell culture: Cells were cultured at 37°C in an atmosphere maintained at 95% humidity and 5% CO .

[0102] Bone marrow-derived dendritic cells (BMDCs):Isolation and Extraction: C57BL / 6 mice were sacrificed on day 1. Femurs and tibias were removed, and muscle tissue was cleaned and separated using sterile scissors. The bones were washed in a Petri dish containing 70% EtOH for 5 seconds, followed by cRPMI. A 10 mL syringe was filled and fitted with a 27G needle. The tips of the femurs and tibias were minimally cut and placed in a Petri dish containing fresh cRPMI. The bone marrow was flushed into the Petri dish by inserting a 27G needle and injecting cRPMI. Cell clumps were broken up by repeated gentle pipetting with a 19G needle. The cells were transferred to a 50 mL Falcon tube and spun down at 1200 rpm for 5 minutes. The supernatant was removed, and 1 mL of 0.88% NH4Cl red blood cell lysis solution was added. After 2 minutes, the reaction was stopped with 25 mL of cRPMI. The cell mixture was centrifuged at 1200 rpm for 5 minutes. The supernatant was removed. The cell pellet was resuspended in 10 mL of cRPMI. Cell numbers were counted using the trypan blue exclusion method (section 2.2.2.2). The volume of the cell suspension was adjusted with cRPMI containing 20 ng / mL GM-CSL to a final concentration of 4.25 × 10 5 The cells were transferred to a T175 flask (12.75 × 10 6 (cells / flask). From day 1, careful handling of the T175 flasks was performed to avoid DC activation. On day 3, 30 mL of cDMEM containing 20 ng / mL GM-CSP was added to each T175 flask. On day 6, the flask supernatant was removed and replaced with 30 mL of fresh cRPMI containing 20 ng / mL GM-CSP. On day 7, 30 mL of cRPMI containing 20 ng / mL GM-CSP was added to each T175 flask. On day 10, loosely adherent cells were removed by gentle repeated pipetting. The cells were transferred to a 50 mL Falcon tube and spun down at 1200 rpm for 5 minutes. The supernatant was discarded, and the cell pellet was resuspended in 10 mL of RPMI. The cell mixture was diluted to 6.25 × 10 cells / ml in cRPMI containing 10 ng / mL GM-CSP (unless otherwise stated). 5The final concentration of cells / mL was 100 μL. Cells were plated in round-bottom 96-well plates at 200 μL / well for cytokine analysis or in 12-well flat-bottom plates at 950 μL / well for FACs and qPCR analysis. Plates were incubated at 37°C with 5% CO for at least 2 hours before stimulation.

[0103] Measurement of cytokine secretion by ELISA IL-6 concentrations were measured using an antibody from BD Biosciences (BD 555240). IFN-β was detected using an antibody from Santa Cruz Biotechnology (capturing antibody #sc-57201) and an antibody from R&D systems (detection antibody #32401-1). IFN-γ (DY485), CXCL10 (DY466), and IL-1β (DY401) ELISA kits were purchased from R&D systems.

[0104] Flow cytometry analysis of cell death: BMDCs, 1 x 10 in a 12-well round flat-bottom plate 6 Cells were seeded at 1000 cells / mL. After 24 hours of treatment with the chitin derivative, the plates were centrifuged and the supernatant discarded. Cells were removed from the wells with ice-cold PBS, transferred to labeled FACS tubes, and washed with 2 mL of PBS. After washing and spinning down, cells were stained with fixable viability stain 510 in PBS (400 μL: 1:1000 dilution) or A700 in PBS for 15 minutes at room temperature. Cells were then washed twice with PBS, resuspended in 200 μL of FACS buffer (2% fetal calf serum (FCS) in PBS), and immediately acquired. Data were analyzed using Flowjo™ software (Treestar, Oregon).

[0105] Detection of costimulatory molecule expression in dendritic cells Cells were stained with Fixable Viability Stain 510, centrifuged at 400 × g for 5 minutes at 4°C, and resuspended in 100 μl of FACS buffer containing purified anti-mouse CD16 / CD32 to block FcγRII / III. Cell surface staining was then performed by adding 10 μl of fluorochrome-conjugated antibodies against CD40, CD80, and CD86. Samples were acquired using a BD FACSCANTO II with Summit software (Dako, CO), and data were analyzed using Flowjo™ software (Treestar, OR).

[0106] Flow cytometry analysis of mitochondrial reactive oxygen species: BMDCs were plated in a 12-well round flat-bottom plate at 1 x 10 6 Cells were seeded at 1000 cells / mL. After 1.5 hours of treatment with the chitin derivative, the plates were centrifuged and the supernatant discarded. As a positive control for mitochondrial reactive oxygen species (mtROS), cells were treated with rotenone (5 μM) for 6 hours. Cells were removed from the wells using ice-cold PBS, transferred to labeled FACS tubes, and washed with 2 mL of PBS. After washing and spinning down, cells were co-stained with fixable viability stain 510 (200 μL: 1:1000 dilution) and MitoSox Red (500 μL: 1:5000 dilution) in PBS for 15 minutes at room temperature. Cells were then washed twice with PBS, resuspended in 200 μL of FACS buffer, and immediately acquired. Data were analyzed using Flowjo™ software (Treestar, Oregon).

[0107] Flow cytometry analysis of DNA damage. DNA fragmentation was measured using the Apo-TUNNEL DNA damage kit as follows: BMDCs were plated in a 12-well round flat-bottom plate at 1 x 10. 6Cells were seeded at 1000 cells / mL and treated with chitin derivatives (5 μg / mL) for 3 or 9 hours. As a positive control, cells were treated with etoposide (100 μM) for 24 hours. Cells were removed from the wells using ice-cold PBS, transferred to labeled FACS tubes, and washed with 2 mL of PBS. Cells were stained with A700 viability dye (400 μL; 1:1000 dilution) for 15 minutes at room temperature. After the time interval, cells were washed and fixed with 1% PFA for 15 minutes. Cells were washed as before and permeabilized overnight in pure ethanol at -20°C. The following morning, cells were washed and stained for 1 hour at 37°C with DNA labeling solution containing reaction buffer (10 μL / sample), TdT enzyme (0.75 μL / sample), BrdUTP (8 μL / sample), and dH2O (31.25 μL / sample). NOTE: FACS tubes were shaken every 15 min to keep cells suspended. After 1 h, cells were washed with rinse buffer (provided in the kit) and stained with 100 μL of antibody staining solution (10 μL of Alexa 488 anti-BrdU Ab and 90 μL of rinse buffer) for 30 min at room temperature. Without washing, 200 μL of PI / RNase A staining buffer was added to each FACS tube already containing the antibody staining solution. Cells were analyzed on a FACSCanto 30 min to 2 h after addition of the PI / RNase A buffer, and data were analyzed using Flowjo™ software (Treestar, Oregon).

[0108] Flow cytometry analysis of costimulatory molecule expression on B16-F10 cells: 2 x 10 in a 24-well plate 5B16 melanoma cells were stimulated with medium or 40 μg / ml C90, C100, or protasan for 24 hours. Cells were removed from wells with ice-cold PBS-EDTA, transferred to labeled FACS tubes, and washed with 2 mL of PBS. Cells were stained with BV510 viability dye (1:1000 dilution) for 15 minutes at room temperature. Cells were then washed with PBS and stained for cell surface markers for 30 minutes at room temperature. Cells were then washed with PBS and resuspended in 200 μl of FACS buffer. Samples were acquired on a BD FACSCanto, and data were analyzed using Flowjo™ software (Treestar, Oregon).

[0109] Quantitative polymerase chain reaction:

[0110] Q-PCR RNA was isolated using the High Pure RNA Isolation Kit (Roche) and reverse transcribed into complementary DNA (cDNA) using M-MLV reverse transcriptase (RNase H-free, point mutation, Promega). Quantitative PCR was performed using the KAPA SYBR FAST qPCR Kit Master Mix (2X) (KAPA Bio-systems) according to the manufacturer's instructions using the Aligent Technologies Stratagene Mx3005P protocol. The following primers were used (5' to 3'): Actb forward: TCCAGCCTTTCTTGGT, Actb reverse: GCACTGTGTTGGCATAGAGGTC, S18 forward, S18 reverse, Ifnb forward: ATGGTGGTCCGAGCAGAGAT, Ifnb reverse: CCACCACTCATTCTGAGGCA, Ifna forward: ATGGCTAGGCTCTGTGCTTTCCT, Ifna reverse: AGGGCTCTCCAGAGTTCTGCTCTG. RNA expression was normalized to β-actin and s18 expression, as well as expression in relevant untreated control samples.

[0111] Mitochondrial DNA depletion in BMDCsCells were cultured as normal until day 6, when the medium was changed to 30 mL of RPMI containing 20 ng / mL GM-CSF and 150 ng / mL ethidium bromide. On day 7, an additional 30 mL of RPMI containing 20 ng / mL GM-CSF and 150 ng / mL ethidium bromide was added to the T175 flask. On day 10, loosely attached cells were removed by gentle pipetting, washed, and resuspended in RPMI containing 10 ng / mL GM-CSF. 5 x 10 6 Cells were harvested to confirm mtDNA depletion, and the remainder were plated for stimulation.

[0112] Quantification of mitochondrial DNA depletion : DNeasy Blood and tissue kit culture cells according to the protocol. 6 Total DNA was isolated from cells, and mitochondrial depletion was quantified by qPCR using primers specific for the mitochondrial D-loop region (dloop) or for regions of mtDNA not inserted into nuclear DNA (non-NUMT), as well as primers specific for nuclear DNA (Tert, B2m).

[0113] Western Blot:

[0114] Sample preparation BMDCs were cultured in a 12-well plate at 1 × 10 6 Cells were seeded at 1000 cells / mL and allowed to rest for at least 2 hours before stimulation. Cells were lysed in 150 μL of Lamelli buffer containing 1% protease inhibitors (1 / 100 dilution) and 1% phosphatase inhibitors (1 / 100 dilution) and left on ice for 5 minutes. After 5 minutes, the Lamelli-cell mixture was transferred to an Eppendorf tube and heated in a heating block at 95°C for 5 minutes.

[0115] Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis An SDS polyacrylamide gel was prepared. Air bubbles were removed from the lower gel using isopropanol and poured off before adding the stacking gel. The gel was placed in an SDS electrophoresis stand with the plate facing inward. The SDS stands containing the two gels were placed in an SDS apparatus, and the center column was filled to the top with SDS running buffer. The center SDS stand was checked for leaks. The combs were removed from the two gels to expose the lanes for protein loading. Sample (20 μL) and protein ladder (7 μL + 13 μL Lamelli buffer) were added to the lanes. To ensure that the proteins migrated at the same rate through the gel, 20 μL Lamelli buffer was added to the remaining empty lanes. Once fully loaded, the outside of the SDS apparatus was filled with running buffer up to the silver electrode. The apparatus was then attached to a power pack and operated at 80 V for 30 minutes (or until the Lamelli buffer had passed through the stacking gel). The voltage was then increased to 100 V until the smallest protein band (10 kDa) was at a distance of 5 mm from the bottom of the plate.

[0116] Protein transfer: semi-dry method. Two gels were removed from the central SDS stand. The top tray was carefully removed to expose the gel. The gel was quickly immersed in transfer buffer. Two 1.5 mm filter paper strips were cut, each slightly wider than the gel, and immersed in transfer buffer. PVDF was cut to the same size as the gel and activated in methanol for 2 minutes, followed by two 2-minute washes in water and transfer buffer. One soaked filter paper was placed on the transfer apparatus. The activated PVDF membrane was then placed on top of the filter paper. The gel was carefully removed from the transfer buffer and placed on top of the PVDF membrane. A second soaked filter paper was placed on top of the gel. Carefully, air bubbles were removed with a roller, taking care not to dislodge the gel from the PVDF membrane. The gel was transferred at a speed dependent on the size of the protein of interest. For example, a 40 kDa protein was transferred at 50 mAmps per gel for 1 hour and 30 minutes. When transferring two gels simultaneously, set the transfer device to 100mAMPs and transfer for 1 hour and 30 minutes. Note: Do not transfer more than four gels per transfer device. When finished, place the PVDF membrane into a 50mL tube with the gel-contacting side of the membrane facing the center of the tube.

[0117] blocking Proteins were blocked with 10 mL of 3% BSA in TBST for 1 hour at room temperature or overnight at 4° C. Note that the 50 mL tubes are placed on a rotator to ensure uniform blocking of the membrane.

[0118] complementary antibodies The blocking buffer was removed from the 50 mL tube and replaced with 3 mL of primary antibody solution. The tube was placed on a rotator at 4°C overnight.

[0119] secondary antibody The primary antibody mixture was poured off, and the membrane was washed three times with TBST for 5 minutes each. The gel was then placed in the secondary antibody solution and left on a rotator for 1 hour at room temperature. After 1 hour, the gel was washed three times with TBST for 5 minutes each. If the protein of interest was not phosphorylated, the membrane was further washed twice with PBS for 5 minutes each. The blots were analyzed on an Odyssey LI-COR instrument, with the intensity set to 5 in the 700 channel and 6 in the 800 channel, and the resolution set to 169 μm. Images were analyzed using Image Studio Lite software.

[0120] Models of tumor prevention: Ten-week-old C57BL / 6J mice were subjected to an initial boost vaccination regimen, including intramuscular immunization with PBS, OVA peptide alone (10 μg), C100 (200 μg) + OVA peptide (10 μg), C90 (200 μg) + OVA peptide (10 μg), or Protasan (200 μg) + OVA peptide (10 μg) on ​​days 0 and 14. B16-F10 cells constitutively expressing OVA (B16-F10-OVA) were cultured in vitro using T175 cell culture flasks. Upon reaching logarithmic growth phase (<50% confluence), cells were harvested using trypsin EDTA. Cells were washed, counted, and resuspended in ice-cold HBSS at the appropriate concentration. Subsequently, mice were subcutaneously injected with 3.5 × 10 cells / mL of OVA peptide into the right flank. 5 Each mouse was loaded with 1000 B16-F10-OVA cells. Tumor growth was measured daily, and tumor volume was determined by the following formula: volume = (length × (width) 2 ) / 2. Mice were culled at a humane endpoint determined to have reached a diameter of 15 mm.

[0121] Models for Tumor Treatment B16-F10-OVA cells were cultured in vitro using T175 cell culture flasks. When they reached the logarithmic growth phase (<50% confluence), they were harvested using trypsin-EDTA. Cells were washed, counted, and resuspended in ice-cold HBSS at the appropriate concentration. 12-week-old C57BL / 6J mice were inoculated with 3.5 × 10 cells into the right flank. 5Each tumor was loaded with 16-F10 cells. Tumor growth was measured daily, and tumor volume was calculated as (length × (width)). 2 ) / 2. 3 At the time of tumor size, mice were randomized into experimental groups in a block fashion and administered PBS or C100 (200 μg) intratumorally. Three days later, the same treatment was repeated. Tumor volume (as previously determined) was then measured daily. Mice were humanely terminated when they reached a diameter of 15 mm.

[0122] [Table 1]

Claims

1. A pharmaceutical composition for immunotherapy for the prevention or treatment of cancer, comprising: an adjuvant, said adjuvant comprising polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups; A pharmaceutical composition, wherein the N-acetyl-D-glucosamine groups are distributed in two or more blocks in the acetylated polyglucosamine.

2. 2. The pharmaceutical composition of claim 1, wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of 10 or more.

3. A pharmaceutical composition described in claim 1 or 2 for use in combination with a tumor antigen.

4. The antigen is a TAA (tumor associated antigen) peptide mix, P10s-PADRE, PR1 peptide, neoantigen, MUC-1, pBCAR3 peptide, MAGE-A3, MAG-Tn3, PRAME, neoantigen, Bcl-XL, NY-ES0-1, WT1 peptide, GAA / TT-peptide, NY-ES0-1b, URLC10-177, MAGE-3.1, gp100, Pros. spec peptide, ras peptide, THERATOPE, Globo H-GM2, or sialyl Lewis. a 4. The pharmaceutical composition of claim 3, wherein the compound is selected from the group consisting of (CA19-9), MUC-2-KLH, NY-ESO-1, CDX-1401, CDX-1307, tumor lysate, CDX-1401, HER2 peptide, ALVAC-NY-ESO-1, CMB305, IDC-0305, MB305, SVN53-67-KLH, PR1 peptide, MART-1, and rsPSMA; or a combination thereof.

5. The pharmaceutical composition described in claim 3 or 4, wherein the antigen comprises a neoantigen.

6. The pharmaceutical composition of claim 3, wherein the antigen comprises a tumor lysate, a tumor extract or a killed tumor cell.

7. For use as a vaccine in combination with other therapeutically or prophylactically active substances; 7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the therapeutically or prophylactically active substance optionally comprises an agonist of CpG, toll-like receptor, nod-like receptor, C-type lectin receptor, AIM2-like receptor or other pathogen recognition receptor, or a combination of pathogen recognition receptor agonists, or consists of an agonist of CpG, toll-like receptor, nod-like receptor, C-type lectin receptor, AIM2-like receptor or other pathogen recognition receptor, or a combination of pathogen recognition receptor agonists.

8. A pharmaceutical composition for immunotherapy for solid cancer, comprising polyglucosamine or chitosan, for administration into and / or around the tumor.

9. 9. The pharmaceutical composition of claim 8, wherein the polyglucosamine or acetylated polyglucosamine has a molecular weight of at least 100 kDa.

10. 10. The pharmaceutical composition according to claim 8 or 9, wherein the acetylated polyglucosamine is chitosan and is at least 10% deacetylated or contains up to 90% N-acetyl-D-glucosamine groups.

11. The pharmaceutical composition according to any one of claims 8 to 10, wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in two or more blocks.

12. The pharmaceutical composition according to any one of claims 8 to 11, wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of 10 or more.

13. Used in combination with other therapeutic agents; Optionally, the therapeutic agent is a checkpoint inhibitor for the treatment of cancer; and / or Optionally, the therapeutic agent comprises CpG, MPL or other pathogen recognition receptor agonist, or a combination of pathogen recognition receptor agonists, or consists of CpG, MPL or other pathogen recognition receptor agonist, or a combination of pathogen recognition receptor agonists; The pharmaceutical composition according to any one of claims 8 to 12.

14. 14. The pharmaceutical composition of claim 13, wherein the checkpoint inhibitor is selected from an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA-4 antibody, an anti-TIGIT antibody, and a CD40 agonist antibody; or selected from nivolumab, pembrolizumab, atezolizumab, avelumab, and tiragolumab, or an antibody that targets the same protein or pathway as, or competes for binding with, an antibody selected from any of nivolumab, pembrolizumab, atezolizumab, avelumab, and tiragolumab.

15. A pharmaceutical composition described in any one of claims 8 to 14, used in combination with an adjuvant and / or a cytokine.

16. A pharmaceutical composition according to any one of claims 8 to 14, which is not used as an adjuvant and / or is not used in combination with a vaccine or antigen.

17. An adjuvant composition for use in combination with an antitumor vaccine for cancer immunotherapy, said adjuvant composition comprising polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, said N-acetyl-D-glucosamine groups being distributed in two or more blocks in said acetylated polyglucosamine.

18. A composition comprising an adjuvant and an anti-tumor antigen, wherein the adjuvant comprises polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, and the N-acetyl-D-glucosamine groups are distributed in two or more blocks in the acetylated polyglucosamine.

19. i) an adjuvant; and ii) Antitumor Antigens A kit comprising: A kit, wherein the adjuvant comprises polyglucosamine or an acetylated polyglucosamine containing 10% or less N-acetyl-D-glucosamine groups, the N-acetyl-D-glucosamine groups being distributed in two or more blocks in the acetylated polyglucosamine.

20. A composition comprising polyglucosamine or acetylated polyglucosamine formulated for intratumoral and / or peritumoral administration.

21. 21. The composition of claim 20, wherein the acetylated polyglucosamine contains 10% or less N-acetyl-D-glucosamine groups, and the N-acetyl-D-glucosamine groups are distributed in two or more blocks in the acetylated polyglucosamine.

22. 22. The composition of claim 20 or 21, further comprising a therapeutic agent comprising one or more of a checkpoint inhibitor and / or a CpG, MPL or other pathogen recognition receptor agonist or a combination of pathogen recognition receptor agonists.

23. 21. A kit comprising the composition of claim 20 and a therapeutic agent comprising one or more of a checkpoint inhibitor and / or a CpG, MPL or other pathogen recognition receptor agonist or combination of pathogen recognition receptor agonists.